JavaScript is disabled for your browser. Some features of this site may not work without it.
TRH attenuates scopolamine-induced memory impairment in humans
Cohen, Martin R.; Weingartner, Herbert J.; Sunderland, Trey; Lawlor, Brian A.; Cohen, Robert M.; Molchan, Susan E.; Mellow, Alan M.
1990-03
Citation:Molchan, Susan E.; Mellow, Alan M.; Lawlor, Brian A.; Weingartner, Herbert J.; Cohen, Robert M.; Cohen, Martin R.; Sunderland, Trey; (1990). "TRH attenuates scopolamine-induced memory impairment in humans." Psychopharmacology 101 (1): 84-89. <http://hdl.handle.net/2027.42/46332>
Abstract: The brain tripeptide thyrotropin-releasing hormone (TRH) has been demonstrated to facilitate cholinergic neurotransmission. To test its interaction with the cholinergic system in humans, high-dose TRH (0.5 mg/kg) or placebo was administered intravenously (IV) to normal controls pretreated with scopolamine (0.5–0.75 mg IV), a centrally active muscarinic antagonist, which has been used to model aspects of the memory impairment of normal aging and of dementia. Compared to placebo, TRH markedly attenuated scopolamine-induced impairment of some measures of memory, most notably on a selective reminding task. This cognitive study is the first in humans to suggest a neuromodulatory effect of a peptide on the cholinergic system, and suggests a facilitatory role for TRH in human memory processes.
